arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Altimmune, Inc.

ALT
$3.41 ▲ +0.15 (+4.60%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
17 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
35
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Altimmune, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $300.4M
Dividend Yield
Revenue Growth 105.0%
Op. Margin None
ROIC -36.2%
FCF / Share $-0.77
Trailing P/E
Price / Book 1.7x
FCF Yield
Debt / Equity 0.15
info Valuation on last close. End-of-day price, Sep 22, 2026.

17-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$41.00K
↑ +105.0%
Net Income Profit after all expenses
$-88.09M
↑ +7.3%
Operating Margin Operating profit as % of sales
-370.0%
↑ +10.8%
FCF / Share Free cash flow per share
$-0.77
↑ +31.8%
Long-Term Debt Long-term obligations
$34.29M
↑ +648.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
19
Financial Health
45
Cash Quality
52

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 17 years · 67 quarters